Radioquimioterapia neoadjuvante no câncer de reto: avaliação de 10 pacientes

Abstract

Introduction: Rectal cancer is a common and lethal disease, with difficult local control. Neoadjuvant chemoradiotherapy followed by surgery is the standard treatment for locally advanced disease. Objectives: Gather data of the patients with rectal cancer and assess the neoadjuvant treatment as for correct application of the therapeutic scheme, clinical response, pathologic response, and incidence of complications. Methods: Charts have been reviewed from 10 patients who were treated with neoadjuvant chemoradiotherapy for rectal cancer on the period of august 2012 to September 2013. Results: There was complete clinical response do neoadjuvant chemoradiotherapy in 20% of the cases. Incomplete clinical response was seen in 80% of the cases. Seven patients were assessed for pathological response with 43% defined as intermediate response and 57% as poor response. As for complications, 20% presented with some form of acute complication, such as diarrhea and actinic rectitis. There was one death. The average time between the end of neoadjuvant chemoradiotherapy and surgery was 13,1 weeks. Conclusion: The chemoradiotherapy scheme was correctly administered though the interval between that and the surgery was slightly longer than suggested. The rate of complete clinical response to neoadjuvant treatment was close to that found on the literature. The rates of pathologic response were on the interval found on the literature. The complications rate also was smaller than that found on the literature.